Prevention of Cefoperazone-induced Coagulopathy

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Helwan University
• Treatments: Vitamin K

Criteria

Inclusion Criteria:

• ICU admitted patients on treatment or prophylactic doses of cefoperazone/sulbactam.

Exclusion Criteria:

• Patients' aged <18 years

• Pregnancy or breastfeeding women

• Active bleeding or bleeding disorder

• Patients having an abnormal baseline coagulation profile.

• Patients administer total parenteral nutrition with regular vitamin k supplements.

• Refusal to sign the written informed consent.